Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177295 | 0.83 | HTR2C (0.47) | CYP1A2HTR2CALDH1A1KMT2ALMNA | |
| SCHEMBL1177410 | 0.83 | HTR2C (0.36) | CYP1A2HTR2CCA2LMNACA1 | |
| SCHEMBL1574977 | 0.82 | HTR2C (0.53) | CYP1A2HTR2CALDH1A1KMT2ALMNA | |
| SCHEMBL1177525 | 0.81 | HTR2C (0.44) | CYP1A2CYP2C9HTR2CALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL1178042 | 0.80 | HTR2C (0.51) | CYP1A2HTR2CALDH1A1KMT2ALMNA | |
| Hexaminolevulinate SCHEMBL1177698 | 0.80 | HTR2C (0.65) | CYP1A2CYP2C9HTR2CALDH1A1CA2 | |
| SCHEMBL1177415 | 0.79 | ALDH1A1 (0.54) | CYP1A2CYP2C9ALDH1A1CA2CA9 | |
| Methyl Aminolevulinate SCHEMBL1177327 | 0.78 | LMNA (0.56) | CYP1A2CYP2C9ALDH1A1KMT2ALMNA | |
| SCHEMBL1177508 | 0.77 | ALDH1A1 (0.51) | CYP1A2CYP2C9ALDH1A1CA2KMT2A | |
| SCHEMBL1177430 | 0.76 | LMNA (0.62) | CYP1A2CYP2C9ALDH1A1CA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8692014-B2 | Acid addition salts of 5-aminolevulinic acid or its derivatives | PHOTOCURE ASA (NO) | 2014-04-08 | — | — | US | disclosed |
| US-20110125012-A1 | ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES | BRAENDEN JON ERIK | 2011-05-26 | — | — | US | disclosed |
| EP-2308830-A1 | Acid addition salts of 5-aminolevulinic acid or its derivatives | Photocure ASA (NO) | 2011-04-13 | — | — | EP | disclosed |
| US-7888526-B2 | Nonhygroscopic photosensitizing agents; sulphonate, hydrobromide, sulfate, nitrate and/or phosphate derivatives; diagnosing skin disorders | PHOTOCURE ASA (NO) | 2011-02-15 | — | — | US | disclosed |
| US-20080064752-A1 | Acid Addition Salts Of-5-Aminolevulinic Acid Or Its Derivatives | PHOTOCURE ASA (NO) | 2008-03-13 | — | — | US | disclosed |
| EP-1727786-A1 | ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES | Photocure ASA (NO) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005092838-A1 | ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES | PHOTOCURE ASA (NO) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064752-A1 | Acid Addition Salts Of-5-Aminolevulinic Acid Or Its Derivatives | ALAD, AASDHPPT, ABAT | CYP1A2 1812/4885CYP2C9 1495/4885HTR2C 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.